← Back to Screener
SAB Biotherapeutics, Inc. Common Stock (SABS)
Price$3.38
Value ScoreD
Growth ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-22.36%
Price vs S&P 500 (4W)-17.75%
VGM Score33.79
Market Capitalization$258.45M
P/E Ratio (Annual)19.47x
All Metrics
Book Value / Share (Quarterly)$3.00
P/TBV (Annual)1.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-72.10%
Cash Flow / Share (Quarterly)$-0.70
Price vs S&P 500 (YTD)-17.78%
Net Profit Margin (TTM)-1795.85%
EPS (TTM)$-1.42
10-Day Avg Trading Volume0.34M
EPS Excl Extra (TTM)$-1.42
EPS (Annual)$0.22
ROI (Annual)8.58%
Net Profit Margin (5Y Avg)-906.73%
Cash / Share (Quarterly)$1.42
P/E Basic Excl Extra (TTM)19.47x
EPS Growth (5Y)-50.72%
P/E Normalized (Annual)19.47x
ROA (Last FY)7.68%
Revenue Growth TTM (YoY)-92.42%
EBITD / Share (TTM)$-1.35
ROE (5Y Avg)-60.20%
Operating Margin (TTM)-2388.92%
Cash Flow / Share (Annual)$-0.96
P/B Ratio1.14x
P/B Ratio (Quarterly)1.13x
Net Income / Employee (Annual)$154,300
EV / Revenue (TTM)182.31x
Net Interest Coverage (TTM)-52.02x
ROA (TTM)12.51%
EV / EBITDA (TTM)22.33x
EPS Incl Extra (Annual)$0.22
Current Ratio (Annual)9.46x
Quick Ratio (Quarterly)11.06x
3-Month Avg Trading Volume0.65M
52-Week Price Return84.20%
P/E Incl Extra (TTM)19.47x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.29
P/S Ratio (Annual)195.44x
Asset Turnover (Annual)0.03x
52-Week High$6.60
Operating Margin (5Y Avg)-1010.02%
EPS Excl Extra (Annual)$0.22
CapEx CAGR (5Y)-40.71%
26-Week Price Return-14.43%
Quick Ratio (Annual)9.13x
13-Week Price Return-11.29%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)11.45x
Enterprise Value$241.17M
Asset Turnover (TTM)0.02x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2579.03%
Cash / Share (Annual)$2.03
3-Month Return Std Dev68.37%
Net Income / Employee (TTM)$154,300
EBITDA CAGR (5Y)-9.83%
ROE (Last FY)8.76%
Net Interest Coverage (Annual)-80.07x
EPS Basic Excl Extra (Annual)$0.22
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-1.42
Receivables Turnover (Annual)0.00x
ROI (TTM)14.61%
P/S Ratio (TTM)195.37x
Pretax Margin (5Y Avg)-906.71%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.62
Price vs S&P 500 (52W)59.83%
P/E Ratio (TTM)19.47x
Year-to-Date Return-9.63%
5-Day Price Return-1.74%
EPS Normalized (Annual)$0.22
ROA (5Y Avg)-35.54%
Net Profit Margin (Annual)-2579.03%
Month-to-Date Return-6.11%
Cash Flow / Share (TTM)$-0.47
EBITD / Share (Annual)$-0.79
Operating Margin (Annual)-3244.87%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-53.03%
P/E Excl Extra (TTM)19.47x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.42
P/TBV (Quarterly)3.09x
P/B Ratio (Annual)1.18x
Pretax Margin (TTM)-1795.85%
Book Value / Share (Annual)$3.18
Price vs S&P 500 (13W)-19.54%
Beta0.59x
Revenue / Share (TTM)$0.00
ROE (TTM)15.17%
52-Week Low$1.60
vGradeD
gGradeF
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.35est. -0.23
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SABSSAB Biotherapeutics, Inc. Common Stock | D | F | C | $3.38 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing targeted human polyclonal antibodies using its DiversitAb platform, which leverages genetically engineered cattle to produce large quantities of fully human antibodies without human plasma or serum. This differentiated approach enables rapid, scalable production for therapeutic applications.